4D Molecular Therapeutics (FDMT) EBT Margin (2020 - 2025)
Historic EBT Margin for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Q3 2025 value amounting to 63172.22%.
- 4D Molecular Therapeutics' EBT Margin rose 13982277800.0% to 63172.22% in Q3 2025 from the same period last year, while for Sep 2025 it was 174284.17%, marking a year-over-year increase of 6693217200.0%. This contributed to the annual value of 434570.27% for FY2024, which is 4340845500.0% down from last year.
- Latest data reveals that 4D Molecular Therapeutics reported EBT Margin of 63172.22% as of Q3 2025, which was up 13982277800.0% from 363980.0% recorded in Q2 2025.
- 4D Molecular Therapeutics' 5-year EBT Margin high stood at 169852.63% for Q4 2023, and its period low was 4965000.0% during Q4 2024.
- For the 5-year period, 4D Molecular Therapeutics' EBT Margin averaged around 416806.39%, with its median value being 12394.98% (2023).
- Its EBT Margin has fluctuated over the past 5 years, first tumbled by 2000000000bps in 2024, then soared by 2000000000bps in 2025.
- Quarter analysis of 5 years shows 4D Molecular Therapeutics' EBT Margin stood at 27256.52% in 2021, then surged by 92bps to 2195.83% in 2022, then surged by 7835bps to 169852.63% in 2023, then plummeted by -3023bps to 4965000.0% in 2024, then soared by 99bps to 63172.22% in 2025.
- Its EBT Margin was 63172.22% in Q3 2025, compared to 363980.0% in Q2 2025 and 343135.71% in Q1 2025.